← العودة إلى الصفحة الرئيسية
الولايات المتحدة · وكالات وأخبار لحظية · PR Newswire

Ascletis Highlights Oral and Long-Acting Injectable Anti-Obesity Preclinical Studies at ObesityWeek® 2026

نشره PR Newswire · الولايات المتحدة منذ 31 د
Ascletis Highlights Oral and Long-Acting Injectable Anti-Obesity Preclinical Studies at ObesityWeek® 2026
PR Newswire

ملخص مفصل

- ASC30_48 FDC, a first-in-class once-daily oral dual fixed-dose combination targeting GLP-1R and GIPR, achieved approximately 52% relative improvement in weight loss compared to…

- ASC30_48 FDC, a first-in-class once-daily oral dual fixed-dose combination targeting GLP-1R and GIPR, achieved approximately 52% relative improvement in weight loss compared to ASC30 alone

- ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist designed for once-monthly to once-quarterly subcutaneous administration, demonstrates long-acting potential and robust weight loss

HONG KONG, Nov. 16, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") recently presented key preclinical results for its oral small molecule GIPR agonist ASC48, GLP-1R/GIPR dual-targeted oral small molecule ASC30_48 FDC (a fixed-dose combination of ASC30 and ASC48), and a long-acting injectable GLP-1R/GIPR/GCGR triple peptide agonist ASC37 at ObesityWeek® 2026, being held November 14 to 17, 2026, in Washington, DC.

The two poster presentations feature in vitro activity and oral pharmacokinetics (PK) of ASC48; weight-loss data for ASC30_48 FDC; and extended PK, in vitro insulin secretion activity and weight-loss activity of ASC37.

ASC30_48 FDC is an in-house developed oral small molecule combination targeting GLP-1R and GIPR, with the potential to become a first-in-class one-pill, once-daily oral treatment for obesity and other metabolic diseases. These preclinical findings across receptor activity, oral pharmacokinetics and body weight reduction support advancing this program into further clinical development.

ASC37 was developed using Ascletis' proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies. By combining agonist activity at GLP-1R, GIPR and GCGR with a long-acting PK profile, ASC37 is designed to offer a potential once-monthly to once-quarterly subcutaneous treatment for chronic weight management, with an injection volume of no more than 1 mL.

1. Greater Weight Reduction Observed with ASC30_48 FDC than with ASC30 Monotherapy in NHPs

In a randomized study, 15 male cynomolgus monkeys were allocated to…

مطلع المقال، مقتطف من PR Newswire. لقراءة المقال كاملًا، افتحه على موقع الناشر.

اقرأ المقال كاملًا على PR Newswire سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.prnewswire.com)

يستحق القراءة أيضًا